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Amyloid β-peptide (Aβ-peptide)-induced oxidative stress is 
thought to be a critical component of the pathophysiology of 
Alzheimer’s disease (AD). New chalcone derivatives, the Chana 
series, were recently synthesized from the retrochalcones of 
licorice. In this study, we investigated the protective effects of the 
Chana series against neurodegenerative changes in vitro and in 
vivo. Among the Chana series, Chana 30 showed the highest free 
radical scavenging activity (90.7%) in the 1,1-diphenyl-2- pic-
rylhydrazyl assay. Chana 30 also protected against Aβ-induced 
neural cell injury in vitro. Furthermore, Chana 30 reduced the 
learning and memory deficits of Aβ1-42-peptide injected mice. 
Taken together, these results suggest that Chana 30 may be a 
promising candidate as a potent therapeutic agent against neuro-
degenerative diseases. [BMB reports 2011; 44(11): 730-734]
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease that is 
strongly correlated with aging, and its prevalence globally has 
dramatically increased as the lifespan of the world’s pop-
ulation has increased. AD is clinically characterized by severe 
memory loss, impairment of cognitive performance and per-
sonality changes (1). Oxidative stress is a key component of 
the AD pathological cascade (2). Oxidative stress, as measured 
by many parameters, including the modification of DNA, lipid 
peroxidation, protein oxidation and ROS formation, has been 
observed in the neurodegenerative brain tissue of AD patients 
(3, 4). Several studies have suggested that amyloid beta (Aβ) 
peptide induced the oxidative stress observed in the neuro-
degenerative AD brain (5-7). The presence of Aβ plaques is 
one of the major pathological hallmarks of AD (8). This dis-
ease is thought to be caused by the accumulation of Aβ to the 
extent that the Aβ level reach a toxic level in the brain (9). It 
has been known that Aβ peptide-induced toxicity is mediated 
by free radicals, which cause lipid peroxidation of neural cell 
membranes via inhibition of antioxidants (10, 11). Proper in-
tracellular balance of oxidants and antioxidants is vital for cell 
function and an imbalance of the oxidative state is involved in 
much of the pathology mediated by free radicals (12). There-
fore, antioxidant therapies have been investigated as a poten-
tial means to reduce reactive oxygen species (ROS)-based 
damage in AD. Natural antioxidant products are thought to be 
promising potential candidate neuroprotective agents because 
natural antioxidants such as phytochemicals have been shown 
to prevent neuronal cell death via scavenging of free radicals 
and enhancing the cellular antioxidant system. 
　Licorice (the roots of Glycyrrhiza inflate) has been used in 
folk medicine to relieve rheumatic and other types of pain and 
is also known to have a healing effect on ulcers (13). Retro-
chalcones, including echinatin and the licochalcone series 
(licochalcone A-E), have been isolated from licorice, and have 
been shown to produce antioxidative effects such as the scav-
enging of superoxide (13), as well as anti-bacterial (14), anti-in-
flammatory (15) and anti-diabetic (16) activities. In this study, 
we synthesized new chalcone derivatives based on retro-
chalcone from licorice and investigated the protective effects 
of these synthesized chalcones on Aβ peptide-induced oxida-
tive damage via free radical scavenging in vitro and determine 
if these chalcones could reduce learning and memory deficits 
in Aβ-treated mice. 
RESULTS AND DISCUSSION
Free radical scavenging activity and the effects on cell 
viability of the Chana series
The free radical scavenging activity of the synthetic chalcone 
series, Chana 1 to 40, was screened using the 1,1-diphenyl-2- 
picrylhydrazyl (DPPH) assay. In this screen, Chana 30 was 
shown to have the highest scavenging activity among the Chana 
compounds (Fig.1B). In fact, the scavenging activity of Chana 
30 was also significantly higher than that of epigallocatechin 
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Fig. 1. Effects of Chana chalcones on PC12 cells. (A) The chemical 
structures of the chalcone backbone and the synthesized Chana 30 
compound. (B) DPPH free radical scavenging activity of the Chana
series was measured. (C) PC12 cells were treated with various concen-
trations (10, 20, and 50 μM) of Chana 28, 29, and 30 in serum-free
media for 24 h. Cells were treated with either Lico A, Lico E, or ascorbic
acid (same concentrations as above) for comparison. EGCG: epigalloca-
techin gallate, Lico E: Licochalcone E. The data are the mean ± SE
(n = 5). Data are represented as mean ± standard error (n = 5).
Fig. 2. Protective effect of the Chana series against Aβ1-42-induced cell
damage. Cell viability of the Chana series was evaluated using the 
MTT assay and the control group was not treated with the test 
samples. PC12 cells were treated with 10 or 20 μM of the Chana 
samples in serum-free media for 24 h. All groups were treated with
25 μM Aβ1-42 except the control group. Cells were also treated with
Lico E at the same concentrations for comparison. Sample treated 
groups were pre-incubated at 10 or 20 μM, in serum-free media for
24 hr before the addition of the Aβ peptide. The data are the mean
± SE (n = 5). #P ＜ 0.05 vs. Aβ-injected group.
gallte (EGCG), which was used as a positive control. Chana 28 
and 29 also exhibited scavenging activities that were higher 
than of the other Chana compounds. To ensure that the com-
pounds with increased scavenging ability were not toxic to 
cells, the viability of PC12 cells was monitored by the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say after the cells were treated with Chana 28, 29, and 30 (Fig. 1 
C). Cells were treated with Chana 28, 29, or 30 at 10 and 20 μM 
for 24 h, and ascorbic acid was used as a positive control. 10 
μM of all three of the Chana series compounds (28, 29 and 30) 
reduced cell viability by less than 20%. Interestingly, the via-
bility of cells treated with the natural retrochalcone, Licochal-
cone E (Lico E), was lower than that of those treated with Chana 
28, 29 or 30.
Protective effects of Chana chalcones against Aβ-induced 
cytotoxicity in vitro
To examine the protective effects of the selected Chana com-
pounds (28-30) against Aβ1-42-induced neuronal cell death, cell 
viability was measured in PC12 cells treated with these com-
pounds and Aβ1-42. Aβ1-42 treatment of PC12 cells decreased 
cell viability by 37.33 ± 1.28% compared to control cells (Fig. 
2). Among the selected Chana compounds, only Chana 30 at 
10 μM significantly protected the cells against the effects of 
Aβ1-42. 
　Aβ peptides have been shown to induce the peroxidation of 
lipids and proteins (10), and this activity may at least in part 
account for the neurodegeneration in AD brains (8). Recent 
evidence has indicated that natural compounds with anti-
oxidant activity can reduce oxidative stress and exhibit neuro-
protective effects. Caffeic acid derivatives from romaine lettuce 
(17), acubin from Eucommia ulmoides japonica (18) and an-
thocyanins from strawberries (19) have all been shown to re-
duce oxidative-induced neurodegenerative damage and retro-
chalcones have been previously reported to have free radical 
scavenging activity (13). In this study, the scavenging activity 
of Chana 30 was found to be similar to that of EGCG and high-
er than that of licochalcone E, and Chana 30 at 10 μM pro-
tected cells from Aβ peptide-induced neuronal cell death (Fig. 
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Fig. 3. Effects of Chana 30 in Aβ-injected mice. (A) Schedule for pretreat-
ment with Chana 30 in vivo. The Y-maze test and the passive avoidance
test were performed to evaluate the in vivo neuroprotective effects 
of Chana 30 at concentrations of 20 and 50 mg/kg. ICR mice were 
treated with Chana 30, Selegiline, or Aricept by oral administration
for 34 days. After 28 days of oral administration, mice were administered
Aβ1-42 (mice who did not receive Chana 30, Selegiline, or Aricept were
administered either Aβ1-42 or Aβ42-1 (control mice) by ICV injection).
Aβ peptides were dissolved in PBS and incubated at 37oC for 24 h 
in order to aggregate prior to injection. Aβ peptides were injected into
each mouse (410 pmol /each) at the bregma by ICV injection. Four
days after the injection of the Aβ peptides, the Y-maze test was performed,
and the passive avoidance test was performed in the following 2 days.
(B) Spontaneous alternation behavior, which is regarded as a measure-
ment of spatial memory, was measured by the Y-maze test in Aβ-injected
mice. (C) Step-through latency (%) was evaluated in a passive avoidance
task in Aβ-injected mice. Chana 30 (20 or 50 mg/kg), Selegiline (3
mg/kg), or Aricept (1 mg/kg) were administered orally for 28 days, 
and mice were ICV injected with Aβ1-42. Control mice were injected
with Aβ42-1. Data are presented as mean ± standard error (n = 8). 
*P ＜ 0.05 vs. the Aβ42-1-injected control group, *P ＜ 0.05 vs. Aβ42-1-in-
jected control group, *P ＜ 0.05 vs. control group, #P ＜ 0.05 vs. 
Aβ1-42-injected group.
2). These results suggest that Chana 30 can potently protect 
against Aβ1-42 induced oxidative damage in vitro and may be 
an efficacious therapeutic agent against Aβ-peptide induced 
cell death via free radical scavenging.
The memory and learning deficits in Aβ1-42-treated mice are 
inhibited by Chana 30
Based on the in vitro neuroprotective effects of Chana 30, we 
performed an in vivo study to investigate the effects of Chana 
30 on the learning and memory deficits in Aβ-treated mice. To 
determine if Chana 30 improved learning and memory, the 
Y-maze and the passive avoidance test were performed. In this 
experiment, Chana 30 was administered orally at a dose of 20 
or 50 mg/kg for 4 weeks (Fig. 3A). We used an AD animal 
model that is based on the intracerebroventricular (ICV) in-
jection of Aβ, which has been previously reported to induce 
memory deficits (20, 21). There were no significant differences 
in body weight between the experimental groups during the 
experiment (Table 1), and all experimental animals survived. 
Pretreatment with Chana 30 was found to dramatically inhibit 
the Aβ-induced decrease in spontaneous alternation behavior 
and treatment with 20 and 50 mg/kg Chana 30 reduced the 
spontaneous alternation behavior to 24.7% and 19.3%, re-
spectively, relative to the untreated control mice, while mice 
injected with only Aβ1-42 displayed a 41.2% decrease in such 
behavior (Fig. 3B). Moreover, the effects of Chana 30 were 
greater than those of the positive controls, Selegiline (12.5%) 
and Aricept (16.8%). 
　In the passive avoidance paradigm, the Aβ1-42-treated mice 
displayed a significantly reduced STL (64% reduction) when 
compared to the control group in the passive avoidance test 
(Fig. 3C). On the other hand, the Chana 30-treated groups had 
STL times of 194 s (20 mg/kg group) and 99.5 s (50 mg/kg), 
both of which were significantly higher than the STL of the 
group treated with only Aβ1-42. In fact, these STL times were al-
so higher than those of the controls and the positive control 
(Selegiline and Aricept) groups, indicating that Chana 30 could 
reduce Aβ-induced learning and memory deficits to a greater 
extent than the positive controls, Selegiline and Aricept, which 
are currently being used to treat Alzheimer’s. 
　In conclusion, Chana 30 protected cells against Aβ pep-
tide-induced oxidative stress and mice against Aβ peptide in-
jection-induced learning and memory deficits. These effects 
likely were the result of the scavenging activity of the newly 
synthesized retrochalcone Chana 30. Taken together, these re-
sults suggest that Chana 30 is a potential potent preventive 
therapeutic agent against AD. 
MATERIALS AND METHODS 
Cell cultures
PC12 cells (a rat pheochromocytoma cell line) were obtained 
from American Type Culture Collection (ATCC, Manassas, VA) 
and were maintained in RPMI-1640 (Gibco BRL, Gaithersburg, 
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Control mice were injected with Aβ42-1. Samples were administrated by oral for 28 days, followed by Aβ42-1 was injected. Data are the mean ± SE (n 
= 8).
Table 1. Changes in body weight of mice co-treated with Aβ and Chana 30
MD, USA) medium that contained 10% heat-inactivated fetal 
bovine serum and 1% penicillin-streptomycin (Gibco BRL). 
Cells were maintained at 37oC in a humidified atmosphere that 
contained 5% CO2.
DPPH free radical scavenging activity 
The DPPH scavenging activity of thirty-four synthetic Chana 
compounds were screened to evaluate their anti-oxidant pro-
perties. The procedure used for this assay was similar to the 
method described by Blois, with slight modifications (22). 
1,000 μg/ml of sample was dissolved in methanol and serially 
diluted to 5, 10, 20, 50, and 100 μg/ml in ethanol. In each re-
action, the solutions were mixed with 0.25 mM DPPH and in-
cubated for 30 min at room temperature. The optical density 
of the solutions was then measured at 517 nm. The DPPH rad-
ical scavenging activity was calculated according to the follow-
ing equation: scavenging activity (%) = [(A0 − A1) / A0] × 
100, where A0 is the absorbance of the blank and A1 is the ab-
sorbance of the sample.
Cell viability measurement
Cell viability was measured by MTT reduction to determine 
the cytotoxicity and/or the neuroprotective effects of the Chana 
chalcones (Chana 28, 29 and 30) at various concentrations on 
PC12 and U87MG cells. MTT reduction was initiated by the 
addition of 10 μl per well of a 2 mg/ml MTT solution. The 
cells were then incubated for 2 h at 37oC. The reaction was 
stopped by the addition of 100 μl dimethyl sulfoxide (DMSO). 
The absorbance was then measured (excitation at 570 nm, 
emission at 630 nm) using a microplate reader (Model 550, 
BIO-RAD, CA). Cell viability was expressed as the relative per-
centage compared to the cell viability of an untreated control 
culture. 
Animals 
Male ICR mice (5 weeks old) were obtained from Samtako Co. 
(Osan, Korea). Animals were allowed to adapt to the environ-
ment for 1 week before experimental use and were maintained 
at constant temperature (23 ± 1oC) and humidity (60 ± 10%) 
and on a 12 h light/dark cycle (light on 07 : 00-19 : 00 h). 
Mice were supplied with a standard pellet diet (Purina Korea) 
and tap water ad libitum. Chana 30 was dissolved in tap water 
at a concentrations of 20 and 50 mg/kg and administered or-
ally daily for 34 days. Aricept (1 mg/kg) and Selegiline (3 
mg/kg) were administered orally for 28 days and used as pos-
itive controls. After 21 days of treatment with Chana 30 or the 
positive control (Aricept and Selegiline), mice were admini-
stered Aβ1-42 by ICV injection (410 pmol/mouse). Mice not 
treated with Chana 30 or a positive control were ICV injected 
with either Aβ1-42 or the non-toxic reverse fragment Aβ42-1 
(control group). Aβ peptides were dissolved in phosphate buf-
fered saline (PBS) and pre-incubated at 37oC for 24 h to allow 
for fibril formation. The peptides were injected into mice (10 
μl per mouse) at the bregma by ICV injection using a Hamilton 
microsyringe (25-G needle, 2.5 mm depth) (26). All experi-
ments were conducted according to the guidelines of the 
Committee on Care and Use of Laboratory Animals of Yonsei 
University. 
Y-maze test
Spontaneous alternation behavior in a Y-maze was used as a 
measure of the short-term spatial recognition memory of 
Chana 30-treated and untreated mice (23). The Y-maze test 
was performed 4 days after Aβ injection. The maze was made 
of black-painted plastic, and each arm of the maze was 33 cm 
long, 15 cm high, 10 cm wide, and positioned at an equal 
angle. Each mouse, all of which had never been exposed to 
the maze previously, was placed at the end of one arm and al-
lowed to freely explore the maze during an 8-min period. 
Passive avoidance test
A step-through passive avoidance test was used to evaluate the 
effects of Chana 30 on Aβ-induced learning and memory defi-
cits (24). The passive avoidance test was carried out 6 days af-
ter Aβ injection. The apparatus (Model PACS-30, Columbus 
Instruments Int.,) was divided into two chambers of equal size 
(23.5 × 15.5 × 15.5 cm). One chamber was illuminated, 
while the other was darkened. During the training trial, each 
mouse was gently placed in the illuminated compartment, and 
when the mouse entered the darkened compartment, the door 
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was closed, and the mouse received an inescapable electrical 
shock (0.5 mA, 1 s). In the test trials, which were given 1 day 
after the training trial, mice were again placed in the lighted 
compartment, and the latency to enter the darkened compart-
ment was measured. If the mouse did not enter the darkened 
compartment within 300 s, the trial was ended, and the mouse 
was assigned a latency of 300 s. 
Statistical analysis
The results were expressed as mean ± standard deviation. 
Differences among means were examined by Duncan’s multi-
ple range tests with SPSS 12.0 (SPSS Inc., Chicago, IL), and a P 
value of ＜0.05 was considered significant.
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